Table 1.

Patient Demographics and Clinicopathology

	DC-CIK Therapy		Chemotherapy		p
Gender					0.013
Men	13	46.4%	29	76.3%
Women	15	53.6%	9	23.7%
Age (years)					0.051
≤65	20	71.4%	18	47.4%
>65	8	28.6%	20	52.6%
Type					0.607
Squamous cell carcinoma	6	21.4%	14	36.8%
Adenocarcinoma	17	60.7%	19	50.0%
Large cell carcinoma	2	7.1%	2	5.3%
Other	3	10.7%	3	7.9%
Size					0.879
<4 cm	16	57.1%	21	55.3%
≥4 cm	12	42.9%	17	44.7%
Involvement of visceral pleura					0.12
No	22	78.6%	23	60.5%
Yes	6	21.4%	15	39.5%
Degree of differentiation					0.018
High	5	17.9%	1	2.6%
Medium	12	42.9%	26	68.4%
Low	11	39.3%	8	21.1%
No data	0	0.0%	3	7.9%
Cutting edge					0.504
≥1cm	28	100.0%	36	94.7%
<1cm	0	0.0%	2	5.3%
Vessel involvement					0.256
No	28	100.0%	35	92.1%
Yes	0	0.0%	3	7.9%
Cleared lymph nodes					0.159
≤6	12	42.9%	10	26.3%
>6	16	57.1%	28	73.7%
Chemotherapy regimen					0.998
Gemcitabine + carboplatin/cisplatin	5	17.9%	7	18.4%
Paclitaxel + carboplatin/cisplatin	4	14.3%	5	13.2%
Vinorelbine + carboplatin/cisplatin	7	25%	9	23.7%
Pemetrexed + carboplatin/cisplatin	12	42.9%	17	44.7%